Bad news for Teva, much-needed good news for the embattled Mylan: The U.S. Patent and Trademark office’s review board struck down two patents on Teva’s new…

Mylan’s EpiPen dilemma won’t be fading soon. After a rush by lawmakers to castigate the company for ‘outrageous’ price increases, Senators Susan Collins (R-ME…

Time and time again, as reports of drug price hikes went viral, pharma and biotech representatives hit back with statements that drug development is expensive…

A federal complaint filed by Turing Chief Commercial Officer Nancy Retzlaff accuses Shkreli friend and Turing co-founder Edwin Urrutia of sexually attacking…

Fresh off its $14 billion deal for Medivation--and in the midst of considering whether to split in two--Pfizer snapped up a portfolio of high-powered…

Pharma companies are discovering that developing apps and digital health technologies is just like developing drugs--at least when it comes to persuading…

Right now, GlaxoSmithKline’s meningitis B vaccine, Bexsero, doesn’t have the key “universal use” endorsement the company wants from the CDC. So it’s spreading…

Mylan has been pummeled by media, consumers, patients, pundits, politicians and even celebrities over charges of jacking up the price for its EpiPen auto…